2018
National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults
Rhee TG, Choi YC, Ouellet GM, Ross JS. National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults. Journal Of The American Geriatrics Society 2018, 66: 1382-1387. PMID: 29582410, PMCID: PMC6097908, DOI: 10.1111/jgs.15357.Peer-Reviewed Original ResearchConceptsNational Ambulatory Medical Care SurveyAnticholinergic prescriptionsPhysician specialtyDrug classesPrescribing trendsOffice-based outpatient visitsOffice-based physician visitsAmbulatory Medical Care SurveyMultivariable logistic regression analysisOlder adultsNational prescribing trendsCommon drug classesLogistic regression analysisCross-sectional analysisSpecific physician specialtiesAnticholinergic medicationsPhysician visitsOutpatient visitsQuality prescribingCare SurveyFemale sexStratified analysisSouthern geographic regionsGreater oddsTotal visits
2017
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA 2017, 317: 1854-1863. PMID: 28492899, PMCID: PMC5815036, DOI: 10.1001/jama.2017.5150.Peer-Reviewed Original ResearchConceptsNovel therapeuticsSafety eventsAccelerated approvalTherapeutic characteristicsUS FoodDrug AdministrationFDA approvalInitial regulatory approvalClinician decision makingNew safety risksMedian followCohort studyMedian timeMultivariable analysisBoxed warningDrug classesMAIN OUTCOMEClinical practicePostmarket periodPsychiatric diseasesPriority reviewTherapeutic areasOrphan statusPsychiatric therapeuticsBiologics
2016
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.Peer-Reviewed Original ResearchConceptsHospital referral regionsOral anticoagulantsReferral regionsDiabetes drugsDrug classesGreater prescribingMedicare Part D beneficiariesAdditional daysPart D beneficiariesMedicare Part D prescriptionsCross-sectional analysisSectional ecological studyMedicare Part DPart D prescriptionsManufacturers of pharmaceuticalsPrescribingAnticoagulantsPhysiciansDrugsPart DEducational materialsSectional analysisStudy limitationsConsulting feesAssociation
2014
Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia
Han LC, Kim SP, Gross CP, Ross JS, Van Houten HK, Smaldone MC, Krambeck AE, Shah ND. Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia. Medical Care 2014, 52: 128-136. PMID: 24423810, DOI: 10.1097/mlr.0000000000000078.Peer-Reviewed Original ResearchConceptsIncident benign prostatic hyperplasiaBenign prostatic hyperplasiaPrimary care providersMedical therapyProstatic hyperplasiaPhysician specialtyNew agentsRespective drug classesAdministrative claims databaseLittle available evidenceRetrospective cohortMedical managementClaims databaseMonths postdiagnosisInsured patientsDrug classesCare providersBlockersReductase inhibitorsPatientsExisting agentsAvailable evidenceUrologistsOverall useHyperplasia